Rho Presenting During the 13th Clinical Trials Innovation Programme (CTIP) 2019 in Boston

May 3, 2019

DURHAM, NC - May 3, 2019 - Rho Presenting During the

13th Clinical Trials Innovation Programme (CTIP) 2019 in Boston

 

WHAT:                 Rho, a full-service contract research organization (CRO), will highlight its clinical trial expertise during the 13th Clinical Trials Innovation Programme (CTIP) 2019, taking place on May 7-8 in Boston, Massachusetts.

 

                                David Shoemaker, senior vice president of research and development at Rho, will be presenting during the conference on right-to-try legislation and expanded access, focusing on the mechanisms for getting access to drugs for serious or life-threatening conditions prior to FDA approval. He’ll share his industry expertise on understanding sponsor responsibilities under these programs and when products may be eligible, evaluating options such as treatment protocols, treatment INDs, and emergency use, and discussing development risks associated with participation in these programs.

 

Rho helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, including clinical operations, project management, data management, data standards, and biostatistics, with extensive experience in many therapeutic areas. To learn more, please visit Rho during the conference.

 

WHO:                    Rho expert at CTIP 2019:

  • David Shoemaker, SVP, Research & Development, Rho

 

WHEN:                 May 7-8, 2019

 

WHERE:               Revere Hotel Boston Common

                               200 Stuart Street

Boston, Massachusetts 02116

 

DETAILS:              For media inquiries, please contact Kelly Maicon at Largemouth Communications,                                             919.741.9784, kmaicon@largemouthpr.com.

 

ABOUT:                Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 35 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com. Follow us on Facebook, LinkedIn and Twitter.